CASI Pharmaceuticals, Inc. (NASDAQ:CASI) saw unusually-strong trading volume on Friday . Approximately 1,616,445 shares traded hands during trading, an increase of 550% from the previous session’s volume of 248,862 shares.The stock last traded at $3.63 and had previously closed at $3.07.
A number of analysts recently issued reports on CASI shares. ValuEngine raised shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 15th. Maxim Group set a $4.00 price target on shares of CASI Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of CASI Pharmaceuticals in a report on Friday, September 8th.
CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.01. analysts anticipate that CASI Pharmaceuticals, Inc. will post -0.15 EPS for the current fiscal year.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
What are top analysts saying about CASI Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CASI Pharmaceuticals Inc. and related companies.